Evidence map›Paper›PMID 40591621›Full record

ArticlePloS one2025

[18F]FDG PET/CT to reduce the need for sentinel lymph node biopsy in early-stage oral cancer: PETN0-study protocol.

Roosmarijn S Tellman, Dominique N V Donders, Anne I J Arens, Koos Boeve, Adrienne H Brouwers, Simone E J Eerenstein, Sylvia L van Egmond, Thomas J W Klein Nulent, W Martin C Klop, Martin Lacko and 8 more

Abstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Roosmarijn S TellmanDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Dominique N V DondersDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Anne I J ArensDepartment of Medical imaging, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-7066-5372
Koos BoeveDepartment of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Adrienne H BrouwersDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Simone E J EerensteinDepartment of Otolaryngology and Head and Neck Surgical Oncology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Sylvia L van EgmondDepartment of Otolaryngology and Head and Neck Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Thomas J W Klein NulentDepartment of Oral and Maxillofacial Surgery and Head and Neck Surgical Oncology, Haaglanden Medical Center, The Hague, The Netherlands.
W Martin C KlopDepartment of Head and Neck Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Martin LackoDepartment of Otorhinolaryngology and Head and Neck Surgical Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands.
Jochem A J van der PolDepartment of Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
Daphne D D RietbergenDepartment of Radiology & Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Robert P TakesDepartment Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-4784-0499
Joris TimDepartment of Nuclear Medicine, Haaglanden Medical Center, The Hague, The Netherlands.
Wouter V VogelDepartment of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Gerben J C ZwezerijnenDepartment of Radiology & Nuclear Medicine, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Bart de KeizerDepartment of Radiology & Nuclear Medicine, University Medical Center Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-6270-9483
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0001-7128-5814

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using reliable techniques for detecting lymph node metastases (LNM) in oral squamous cell carcinoma (OSCC) is crucial for adequate neck treatment. Currently, palpation of the neck, computed tomography, magnetic resonance imaging, ultrasound-guided fine needle aspiration cytology and/or sentinel lymph node biopsy (SLNB) are used to stage the neck in early-stage OSCC. SLNB is a reliable diagnostic technique to detect occult LNM. However, management of the neck with SLNB has its limitations. First of all, SLNB is an invasive procedure with associated morbidity and approximately 20-30% of patients require a subsequent neck dissection. Moreover, performing a subsequent neck dissection is more complex than elective neck dissection, and carries a higher risk of complications. Therefore, it is important to improve patient selection for SLNB. Fluor-18-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has shown promising results for LNM detection. The aim of the PETN0 study, a prospective Dutch multicenter cohort study (registration number NL83442.041.22), is to reduce the need for SLNB by developing scoring criteria for [18F]FDG PET/CT with a high positive predictive value (PPV) in patients with early-stage OSCC. Developing scoring criteria for a high PPV can reduce SLNBs and second-stage neck dissections by performing a neck dissection together with resection of the primary tumor in patients with predicted LNM. When focused on high PPV the sensitivity will probably be lower, but missed LNM will be detected by SLNB when performed after negative [18F]FDG PET/CT. Patients (n = 159) with cT1-3N0 OSCC (8th TNM edition; only when T3 is assessed based on tumor dimensions of >2 and ≤4 cm, with DOI > 10 mm), candidate for transoral excision and SLNB, are included in the study. [18F]FDG PET/CT will be conducted within a maximum of three weeks before SLNB. A cost-effectiveness analysis will also be performed, together with quality of life assessment using questionnaires.

Indexed as

Carcinoma, Squamous CellFluorodeoxyglucose F18Mouth NeoplasmsPositron Emission Tomography Computed TomographySentinel Lymph Node BiopsyFemaleHumansLymphatic MetastasisMaleMulticenter Studies as TopicNeck DissectionNeoplasm StagingProspective StudiesFluorodeoxyglucose F18

Identifiers

PMID40591621
PMCPMC12212575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.